Corbus Pharmaceuticals to Present at the Cystic Fibrosis

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Corbus Pharmaceuticals to Present at the Cystic Fibrosis Workshop Hosted by JMP Securities on May 8, 2015

NORWOOD, MA--(Marketwired - May 4, 2015) - Corbus Pharmaceuticals Holdings, Inc. ( NASDAQ : CRBP ) (the Company), a clinical stage drug development company targeting rare, life-threatening inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at the Cystic Fibrosis (CF) Workshop hosted by JMP Securities on Friday, May 8, 2015, at 10:35 a.m. EDT at The Langham hotel in Boston, MA.

Corbus is preparing to commence a Phase 2, first-in-patient, clinical study with Resunab ™ , its novel synthetic oral drug that has the potential to treat the chronic pulmonary inflammation and fibrosis associated with the disease progression of CF, regardless of an individual's specific CFTR gene mutation.

Dr. Cohen will discuss key milestones achieved by the Company, including the recently announced $5 million Development Award from the Cystic Fibrosis Foundation Therapeutics, Inc.  (CFFT) to help support Corbus' upcoming Phase 2 international clinical trial of Resunab in adults with CF.

Corbus has submitted its Phase 2 clinical protocol for the treatment of CF with Resunab to the U.S. Food and Drug Administration (FDA) and anticipates beginning the study in the U.S. as early as this quarter (2Q 2015), pending FDA clearance of the protocol. The European filing will follow shortly thereafter.

About Cystic Fibrosis CF is a life-threatening, genetic disease that primarily affects the lungs and digestive system. It effects about 30,000 people in the United States (70,000 worldwide). People with CF inherit a defective CFTR gene that results in reduced chloride transport, heightened immune responses and a build-up of thick mucus in the lungs, pancreas and other organs. The thick mucus traps bacteria in the airways resulting in infections and more inflammation. The chronic unresolved lung inflammation leads to severe lung damage and respiratory failure. Respiratory problems are the most serious and persistent complication for individuals with CF. For more information on cystic fibrosis, go to www.cff.org .

About Resunab ™ Resunab ™ is a novel synthetic oral drug with unique activity that has been shown to resolve inflammation and pro-fibrotic processes. Pre-clinical models and Phase 1 clinical studies have shown Resunab to have a favorable safety profile coupled with promising potency in pre-clinical models of inflammation and fibrosis. Resunab binds to the CB2 receptor on immune cells and triggers resolution of inflammation and reduction of pro-inflammatory pathways, in effect turning chronic inflammation "off" without causing immunosuppression.

About Corbus Pharmaceuticals Corbus Pharmaceuticals is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare life-threatening inflammatory and fibrotic diseases. Our lead product candidate Resunab ™ is a novel oral drug that resolves chronic inflammation and pro-fibrotic processes. Resunab is scheduled to commence Phase 2 clinical trials for the treatment of cystic fibrosis and diffuse cutaneous systemic sclerosis (scleroderma) in 2015. For more information, please visit www.CorbusPharma.com .

Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact Jenene Thomas Investor Relations and Corporate Communications Advisor Jenene Thomas Communications, LLC Phone: +1 (908) 938-1475 Email: Email Contact Media Contact David Schull or Marissa Goberdhan Russo Partners, LLC Phone: +1 (858) 717-2310 Email: Email Contact Email: Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 101

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
Disney+ Teams Up with Tiff's: Blue Cookie Debut

Updated Category News Views 10

A Sweet Collaboration on the Horizon If somebody had told me that cookies could conjure up excitement equivalent to a TV show's new season, I'd have laughed. But here we are—Disney+ and Tiff's Treats are cooking up a storm with blue chocolate chip cookies to celebrate 'Percy Jackson and the Olympians' Season 3 premiere. The Cookie That Packs a Punch Forget ordinary...

Continue Reading
2GenPen's Patent Push: Transforming Credit Analysis

Updated Category News Views 111

Changing the Game in Credit Analysis When you hear about a company snagging a patent, it's usually a big whoop-de-do; but 2GenPen's latest achievement is making some serious waves. This isn't some 'pat-yourself-on-the-back' sort of news – it's got teeth in the world of finance. These folks just locked down their second U.S. patent, number 12,784,096, and it's all about...

Continue Reading
Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 49

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 19

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 234

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Life Insurance: Evolving with Your Financial Journey

Updated Category News Views 32

Why Life Insurance Isn't Just a 'Set It and Forget It' Life insurance isn't some one-time deal you lock in and toss aside. Mike Newell, an insurance pro, highlights how life's shifts—whether in income, dependents, or debt—should drive tweaks to your coverage. As your life story unfolds, so too should the backbone of your financial security. Early Adulthood: Setting...

Continue Reading
Sinch Appoints Jonas Dahlberg as New CEO: A Strategic Move

Updated Category News Views 0

A Change at the Helm: Dahlberg Takes Charge Here we go, folks—Sinch, that global powerhouse in customer communications, just got itself a new captain. Jonas Dahlberg is now officially the CEO, after warming the acting CEO seat since June. This ain't your ordinary office shuffle. It's a calculated chess move in the high-stakes tech world. Dahlberg's Path to the Top This...

Continue Reading
LONGWELL's New Axial Fan Selection Guide Unveiled

Updated Category News Views 75

LONGWELL's New Fan Brochure Shakes Up Data Center Cooling Alright, let's cut to the chase. LONGWELL, the folks out in Ningbo who live and breathe HVACR and industrial fans, have dropped a new tool that’s going to have OEM engineers raising a glass. This twelve-page axial fan selection guide is a stroke of genius—or at least that's what those of us who've braved the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 162

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles